• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Seattle Genetics

Seattle Genetics

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape & Competitive Analysis Report 2017 - Research and Markets

    Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape & Competitive Analysis Report 2017 - Research and Markets

  2. FDA Lifts Clinical Hold on Seattle Genetics ’ Phase 1 Trials of Vadastuximab Talirine

    FDA Lifts Clinical Hold on Seattle Genetics ’ Phase 1 Trials of Vadastuximab Talirine

  3. March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics , Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

    March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics , Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

  4. Investor Alert: GPM Reminds Investors of the March 13 Deadline in the Class Action Lawsuit Against Seattle Genetics , Inc.

    Investor Alert: GPM Reminds Investors of the March 13 Deadline in the Class Action Lawsuit Against Seattle Genetics , Inc.

  5. Primecap Odyssey Growth: Stellar Record, Low Fees

    This Gold-rated fund is a fine vehicle for new investors to gain access to the Primecap managers.

  6. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

  7. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

  8. Our Outlook for Health-Care Stocks

    While we remain bullish on the sector, health-care growth depends on the economy.

  9. Our Outlook for Health-Care Stocks

    With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.

©2017 Morningstar Advisor. All right reserved.